DiaMedica Therapeutics (NASDAQ:DMAC) earns an outperform rating from Oppenheimer

Oppenheimer reiterated its outperform rating on the stock DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) in a research report sent to investors on Friday, Benzinga reports. Oppenheimer currently has a $6.00 price objective on the stock.

Separately, Craig Hallum began coverage on DiaMedica Therapeutics in a research report on Wednesday, April 24th. They set a buy rating and a $8.00 price target for the company.

Read our latest report on DiaMedica Therapeutics

DiaMedica Therapeutics stock rose 2.6%

Shares of DMAC stock opened at $3.60 on Friday. The company has a 50-day moving average of $3.09 and a 200-day moving average of $2.95. The stock has a market cap of $153.87 million, a P/E ratio of -6.43 and a beta of 1.50. DiaMedica Therapeutics has a 12-month low of $1.94 and a 12-month high of $3.81.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Your Free Report ) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. In the same quarter last year, the company posted ($0.16) earnings per share. On average, sell-side analysts anticipate that DiaMedica Therapeutics will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling at DiaMedica Therapeutics

In other news, major shareholder Koch Thomas Von acquired 1,200,000 shares of the stock in a transaction dated Friday, June 28th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $3,000,000.00. Following the purchase, the insider now directly owns 5,526,435 shares of the company’s stock, valued at $13,816,087.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Corporate insiders own 7.20% of the company’s shares.

Institutional inputs and outputs

A number of institutional investors have recently made changes to their positions in DMAC. Paragon Associates & Paragon Associates II Joint Venture boosted its position in DiaMedica Therapeutics by 6.4% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after purchasing an additional 30,000 shares during the period. Avantax Advisory Services Inc. purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter valued at about $36,000. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the second quarter worth approximately $87,000. Finally, Vanguard Group Inc. raised its stake in DiaMedica Therapeutics by 26.3% in the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after purchasing an additional 211,351 shares during the last quarter. 10.12% of shares are held by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

(Get a free report)

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, is focused on improving the lives of people suffering from serious diseases, with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in phase II/III trials for the treatment of acute ischemic stroke, as well as in phase 2 for the treatment of cardio-renal disease. .

See Also

Receive news and reviews for DiaMedica Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DiaMedica Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.